Manmeet Singh Soni bought $722K of Summit Therapeutics (SMMT)
Executed Jun 4, disclosed Jun 4, the same day.
Over the 21 trading sessions from the disclosed entry session (Jun 4), the stock returned +6.7% (delay-adjusted); from the execution session (Jun 4), +6.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Manmeet Singh Soni (COO and CFO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Summit Therapeutics Inc. (SMMT). Across 1 priced purchase filing, the average 21-session return was +6.7% from execution and +6.7% from disclosure (delay-adjusted; derived). The largest single filing was $722K of SMMT (50,000 sh across 2 lots, as filed), executed Jun 4.
Healthcare · Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, care…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→